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1 Zusammenfassung 
Das Ziel der Studie war zu untersuchen, ob der Phosphodiesterase Inhibitor Bay 73-6691 
(Bay), den anorektischen Effekt von Amylin verstärkt. Die Versuche basierten auf der 
Hypothese, dass die Hemmung der Phosphodiesterase (PDE) und damit eine Verlangsamung 
des Abbaus von cGMP (dem second messenger von Amylin), die Amylin Wirkung verstärkt.  
 
Unter der Wirkung von Bay kam es allerdings nicht zu einer Verstärkung oder Verlängerung 
des anorektischen Effekts von Amylin, gleichgültig ob Bay peripher oder zentral appliziert 
wurde. Stattdessen konnten wir unter einigen Versuchsbedingungen beobachten, dass Bay 
allein auch bereits zu einer Reduktion der Futteraufnahme führte. Dies könnte bedeuten, dass 
Bay eine Verstärkung des Effekts von endogenem cGMP auslöste. Im folgenden Experiment 
konnten wir ausschliessen, dass der Effekt von Bay auf die Futteraufnahme auf der Induktion 
einer Geschmacksaversion beruhte, d.h. Bay verursachte keine Übelkeit. Letztlich konnten 
wir zeigen, dass Bay die Amylin-induzierte c-Fos Expression im Gehirn erhöhte. 
 
Mit dieser Studie konnten wir zeigen, dass unter den gewählten Versuchsbedingungen Bay 
die Wirkung von Amylin nicht zuverlässig verstärkte. Leider waren einige unserer 
Experimente schwierig zu interpretieren, da wir keinen deutlichen Amylineffekt unter 
Basisbedingungen hatten. Dies könnte an der hohen Konzentration von DMSO liegen, 
welches zum Lösen von Bay verwendet wurde und deshalb auch als Kontrollinjektion diente.  
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2 Summary 
The aim of this study was to investigate if Bay 73-6691 (Bay), an inhibitor of 
phosphodiesterase 9A (PDE), enhances amylin’s anorectic action. We hypothesized that 
inhibition of PDE, resulting in reduced degradation of amylin’s second messenger cGMP, 
would prolong amylin’s anorectic action. 
 
Bay appeared to be unable to reliably enhance or prolong amylin’s effect on eating under 
most test conditions, i.e. peripheral or central administration of Bay. Under some conditions, 
however, Bay treatment reduced food intake, similar to animals receiving amylin. This 
suggests that Bay might enhance the action of endogenous cGMP. In a subsequent experiment, 
we ruled out that Bay decreased eating due to the induction of malaise, as Bay did not 
produce a conditioned taste aversion. Co-treatment of Bay and amylin produced a significant 
increase in c-Fos signaling in the brain, compared to rats treated with Bay/saline. 
 
With this study we showed that under the conditions used, Bay did not reliably enhance 
amylin’s anorectic effect. Unfortunately, some of our experiments were difficult to interpret 
because we found no clear effect of amylin on eating under baseline conditions. Whether this 
was due to an effect of  the high concentration of DMSO used to dissolve Bay and which 
served as control injection in vehicle/amylin treated rats, needs to be elaborated.  
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3 Introduction 
3.1 Obesity problematic  
Obesity and the state of being overweight are defined by the World Health Organization 
(WHO) as an abnormal fat accumulation relative to lean mass, which can lead to health 
problems (WHO, 2013). To assess a person’s body condition, the body mass index (BMI) is 
usually used; the BMI is the weight of a person divided by the square of his/her height. 
However this assessment of body condition is sometimes imprecise because it does not 
differentiate between the lean and the fat mass of a person, and it can also lead to miss 
interpretation in the elderly (Shah and Braverman, 2012). Nevertheless, the evaluation of BMI 
is a valuable initial indicator of a a person’s body condition because it is easy to determine 
and because in most adults, changes in body weight are mainly due to changes in fat and not 
in lean mass. A BMI ≥ 25 is considered as overweight and a BMI ≥ 30 is considered obese.   
 
According to the WHO, worldwide obesity has more than doubled since 1980, and 65 % of 
people live in a country were obesity and the associated diseases kill more people than 
underweight. In 2005, it was predicted that by 2030 the number of overweight or obese 
people would reach 1.35 billion (Kelly et al., 2008). However, these estimations were too 
conservative, because according to the WHO in 2008 there were already 1.4 billion 
overweight adults worldwide, and of these, 200 million men and nearly 300 million women 
were obese. People who suffer from overweight or obesity are at higher risk to develop an 
illness which is associated with excessive weight, like type 2 diabetes, metabolic syndrome, 
fatty liver disease and number of cardiovascular diseases (Malnick and Knobler, 2006), and 
obesity is also associated with higher mortality (Drenick et al., 1980). 
 
The fight against obesity is currently one of the most discussed topics in medicine and a 
variety of approaches can be used to tackle this growing problem. However, many efforts to 
treat obesity successfully have failed. Changes in lifestyle, e.g. by consuming fewer calories 
and burning more calories through increased physical activity, is one of the most obvious and 
least invasive ways to lose weight. However, since changes in lifestyle are often not sufficient 
nor sustainable in the longer term, there is a growing demand for alternative and more 
effective ways to reduce body weight, such as through hormone therapy and surgical 
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intervention. While many mono- and combination hormonal therapies have been developed, 
and often demonstrated promising effects on weight loss initially, most of these treatments do 
not sustain the weight loss in the long term. Alternatively, several types of bariatric surgery 
are available, like gastric banding, sleeve gastrectomy and the Roux-en-Y gastric bypass 
(RYGB); these invasive procedures reportedly have high success rates and seem to be the 
only effective treatments that also lower obesity related mortality and its comorbidities. For 
example, in one study patients undergoing RYGB surgery maintained a loss of 27.7% of the 
initial body weight 6 years after surgery (Adams et al., 2012). However, bariatric surgery is 
invasive, expensive, and reserved for patients who are severely obese. Thus, there is an 
unceasing need for the development of new therapeutic strategies. Ongoing efforts are 
targeting the different peripheral and central mechanisms which mediate satiation, satiety, 
hunger and, therefore, also weight gain and weight loss; however these circuits are not yet 
fully understood. It is only when our understanding of these mechanisms increases, that the 
development of new effective anti-obesity treatments with minimal side effects will be 
possible.  
 
 
3.2 Physiological control of food intake  
Maintenance of body weight homeostasis requires a control of the balance between food 
intake and energy expenditure. Even if daily food intake varies markedly depending on 
emotional and social influences, consumption over a longer time period is more tightly 
controlled. The major controls are mediated by hormonal signals, which are typically gut-
derived. Two groups can be distinguished: the short term satiation signals, which are secreted 
during a meal, and the adiposity signals, which are more tonically secreted, depending on the 
body’s energy stores. 
 
Short-term satiation signals are released primarily from the gut during a meal. The first 
satiation signal discovered was cholecystokinin (CCK), which is secreted by the I cells of the 
duodenal and jejunal mucosa following the ingestion of food (Buffa et al., 1976). Fat, protein 
and amino acids are highly potent stimulators of CCK release, whereas glucose does not 
increase CCK plasma levels as effectively (Liddle et al., 1985). Treatment with exogenous 
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CCK dose-dependently reduces food intake in rats (Gibbs et al., 1997), and it is thought that 
these actions are mediated by CCK1 receptors localized mainly on vagal afferents, but 
perhaps also in the hypothalamus and in the brainstem (Blevins et al., 2000). Additional 
examples of short-acting satiation signals are glucagon-like peptide 1 (GLP-1) and peptide 
YY (PYY). Both hormones are released from the L-cells of the ileum and colon, and act via 
vagal afferents but, depending on the route of administration, perhaps also act centrally to 
inhibit food intake. 
 
The second category, referred to as adiposity signals, are typically secreted in proportion to 
the amount of fat mass, and influence body weight and food intake via access to the central 
nervous system (Woods et al., 1998). This group includes the pancreatic hormones insulin and 
amylin (Morley and Flood, 1991), as well as leptin, which is produced by adipocytes 
(Considine et al., 1996; Maffei et al., 1995). Circulating levels of both leptin and insulin 
correlate to the amount of fat mass (Considine et al., 1996) and when injected in the brain 
cause body weight loss and a reduction in food intake (Woods and Seeley, 2000). However, 
circulating levels of leptin and insulin also fluctuate acutely in response to fasting or eating, 
similar to satiation hormones. 
 
3.2.1 Hypothalamus-hindbrain axis 
The hypothalamic-hindbrain axis plays a vital role in processing hormonal information and 
integrating signals from peripheral tissues like the pancreas, the gut and white adipose tissue 
in order to maintain energy balance. The hypothalamus is located in the mediobasal part of 
the brain, and is composed of different nuclei that control various aspects of energy 
homeostasis, including the ventromedial nucleus (VMH), the lateral hypothalamic area (LHA), 
the paraventricular nucleus (PVH), and the arcuate nucleus (ARH). In addition to these nuclei, 
hindbrain structures, including the nucleus of the solitary tract (NTS) and the area postrema 
(AP), are also key players in the control of energy balance. Peripheral information has 
different ways of reaching these central sites. Some information is mediated through the 
vagus nerve or the spinal cord via vagal or splanchnic afferents. Aside from a few exceptions, 
the brain is protected by the blood brain barrier (BBB), which functions to separate the blood 
from the brain’s extracellular fluid, even though some hormones, like amylin, are able to 
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cross the BBB (Banks et al., 1995). Another route of access is via regions of the brain that 
lack a fully functional BBB, which are called circumventricular organs (CVO). Hormones 
from the blood have direct access to these sites. One example of a CVO is the AP, which 
plays an important role in the hypothalamic-hindbrain axis. 
  
Each of the aforementioned brain nuclei consists of distinct neuronal populations that release 
a variety of neuropeptides or neurotransmitters, which contribute to various aspects of energy 
homeostasis. Located at the base of the hypothalamus, the arcuate nucleus integrates different 
hormonal and neural signals. The ARH harbors two main neuronal populations that each play 
an important role in the control of the food intake; one population promotes anabolic actions, 
while the other mediates catabolic signals (Haskell-Luevano et al., 1999). The catabolic 
system is mainly mediated by proopiomelanocortin (POMC), which is synthesized in a 
subpopulation of ARH neurons. POMC is cleaved to produce melanocyte-stimulating 
hormone (α-MSH), a hormone that acts via melanocortin receptors 3 and 4 in the 
hypothalamus and other areas to produce a strong anorexigenic effect (Cone, 2005). The 
anabolic effect is mediated through neurons that synthesize neuropeptide Y (NPY) and 
agouti-related peptide (AgRP). An increase in these two signals results in a greater drive to 
eat. This is mediated via activation of the Y receptors and by inhibiting the melancortin 3 and 
4 receptor, respectively (Broberger et al., 1998; Cone, 2005; Haskell-Luevano et al., 1999). 
Both insulin and leptin can act directly on ARH neurons to inhibit AgRP/NPY expression and 
to stimulate POMC expression (Cone, 2005). Lying just dorsal to the ARH, is the VMH. 
While the exact phenotype of VMH neurons controlling food intake is unclear, lesions to the 
VMH demonstrably lead to hyperphagia and therefore also obesity (Nakagawa et al., 2000). 
Another study shows that electrical stimulation leads to the opposite effect, such that food 
deprived animals will eat less following stimulation of the VMH (Anand and Dua, 1955). 
While not proven, there is evidence that the VMH is a potential site of interaction for amylin 
and leptin (see below). In an attempt to better define the role of the VMH, Elmquist and 
colleagues searched the brain systematically for the mRNA of the long form of the leptin 
receptor and found out that these are localized in specific nuclear groups in the brain. The 
VMH, together with the DMH, expresses high concentrations of leptin receptor mRNA. In the 
VMH the mRNA is located to the dorsomedial division (Elmquist et al., 1998). Hence, leptin 
can act directly in the VMH, and after administration of leptin c-Fos activation can be seen in 
   
11 
a very similar distribution to the leptin receptor mRNA (Elmquist et al., 1998). If and how 
amylin interacts with leptin in the VMH is yet to be elucidated. 
 
  
3.3 Amylin 
Amylin is a 37 amino acid peptide that is co-secreted with insulin and synthesized by 
pancreatic β cells in response to nutrient stimuli (Cooper et al., 1987; Ogawa et al., 1990). 
During and shortly after food intake, the plasma concentration of both hormones increases. 
Amylin’s primary function is to complement the action of insulin to stabilize glucose 
homeostasis after food intake. Amylin accomplishes this by inhibiting glucagon secretion and 
slowing gastric emptying during and after a meal (Gedulin et al., 2006; Young, 1997). In 
addition to these glucoregulatory effects, amylin also dose-dependently reduces food intake 
after intraperitoneal injection (Lutz et al., 1995). Furthermore, if infused into the hepatic 
portal vein at meal onset, amylin inhibits feeding within minutes by reducing meal size and 
duration, but without having an effect on the following intermeal interval (Lutz et al., 1995). 
Injection of amylin directly into the brain also reduces food intake, while the infusion of the 
amylin antagonist AC 187 can block this effect when given in conjunction with amylin, or 
promote food intake when administered alone (Mollet et al., 2004). It seems that amylin’s 
anorectic effect is specific and not caused by general malaise in the rat, since amylin does not 
elicit a conditioned taste aversion (Morley et al., 1997).  
 
There is strong evidence that peripheral amylin’s anorectic effect depends on activation of 
neurons located in the AP of the hindbrain. Lesions of the AP lead to the loss of amylin’s 
anorectic ability (Lutz et al., 1998), and abolished amylin’s effect on gastric emptying 
(Edwards GL, 1998). The AP expresses a high density of amylin receptors (Sexton et al., 
1994), which are G-coupled protein receptors comprising a core calcitonin receptor (CT-R) 
and receptor modifying activity proteins 1 or 3 (RAMPs; Muff et al., 1999). The occurrence 
of amylin receptors in other brain areas, such as the nucleus accumbens, the VMH, and the 
NTS, has been described (Sexton et al., 1994), but their function still remains to be elucidated 
in respect to the actions of peripheral amylin.  
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C-Fos is a nuclear protein often used as a marker for neuronal activity. In response to 
extracellular signals, this transcription factor is upregulated and exerts either inhibitory or 
stimulatory effects on gene transcription (Curran and Morgan, 1995). When amylin is 
administered in a dose sufficient to reduce food intake, c-Fos can be detected 
immunohistochemically in different regions of the brain, including the AP, the NTS, the 
external lateral parabrachial nucleus (LPBE), the central nucleus of the amygdala (CEA), and 
the lateral division of the bed nucleus of the stria terminalis (BSTL; Riediger et al., 2001; 
Riediger et al., 2004; Rowland et al., 1997). In this manner, the neuronal activation in 
response to amylin can be quantified; importantly, neurons that may be inhibited by amylin 
cannot be detected with the c-Fos technique directly in response to amylin injection. 
Additionally, electrophysiological studies have shown that amylin application directly excites 
AP neurons, and that this effect can be blocked by the amylin antagonist, AC 178 (Riediger et 
al., 2001).  
 
 
3.4 cGMP, phosphodiesterases and phosphodiesterase inhibitors 
Following the binding to its receptor, amylin induces cGMP formation in AP neurons 
(Riediger et al., 2001). cGMP acts as a second messenger in the area postrema and is thought 
to mediate the anorectic response of amylin. This is supported by electrophysiological data 
where the membrane-permeating analog 8-bromo-cGMP, which mimics cGMP accumulation, 
stimulated 65% of all area postrema neurons and 7 out of 9 amylin sensitive neurons 
(Riediger et al., 2001). Additionally, it was shown that direct infusion of 8-bromo-cGMP 
leads to a food intake reduction by reducing meal size, exactly like amylin (Mollet et al., 
2004). Mechanistically amylin’s second messenger cGMP might affect other second 
messenger systems, like cAMP, through the opening of ion-channels or affecting the activity 
of phosphodiesterases in the cytoplasm (Schmidt et al., 1993). 
 
One important regulator of cGMP activity is a group of enzymes called phosphodiesterases 
(PDEs). PDEs are molecules that breakdown intracellular cyclic nucleotides like cGMP and 
cAMP, and came to the general attention as targets for drug development for a wide range of 
different diseases. There are 11 known different PDE families, which each have different 
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splice variants and isoforms. A single cell type can express various different PDE types, 
which have the task to degrade cyclic nucleotides in order to prevent them from accumulating 
and spreading to other areas of the cell. PDEs can be regulated through different mechanisms, 
including stimulation by the Ca2+/calmodulin complex, phosphorylation, and 
dephosphorylation (Bentley, 2005). Allosteric binding to their substrates and protein-protein 
interaction can also regulate the PDE function. 
  
In 1967, caffeine was one of the first described inhibitors of PDEs (Cheung, 1967), and since 
then, many PDE inhibitors have been developed to treat a variety of diseases. One of the most 
famous indications is the PDE5 inhibitor sildenafil (Viagra ®), which is used to treat erectile 
dysfunction but also e.g. pulmonary hypertension. Sildenafil blocks PDE5 from degrading 
nitric oxide-induced cGMP produced in the smooth muscle cells lining the blood vessels of 
the corpus cavernosum. The prolonged action of cGMP causes the muscle to relax and 
increases blood flow to the penis, resulting in a more potent and longer erection (Boolell et al., 
1996; Rajfer et al., 1992). While this is just one example, the same concept is being used to 
target other PDEs which are localized to various tissues in the body. 
 
 
3.5 Phosphodiesterase 9A and its inhibitor Bay 73-6691 
Phosphodiesterase 9A (PDE9A) specifically hydrolyzes cGMP with the highest known 
affinity of any PDE (Fisher et al., 1998; Guipponi et al., 1998). Twenty-one different splice 
variants of PDE9 have been discovered (Rentero et al., 2003), and while the physiological 
relevance of this diversity is not completely understood, it is suggested that the isoforms 
differ in intracellular targeting, biochemical properties and other characteristics (Beavo, 1995).  
 
Analysis of mRNA expression in the rat brain has shown that PDE9A is distributed in the 
basal forebrain, the olfactory bulb, and various cortical and hippocampal regions (Andreeva et 
al., 2001). It seems that the pattern of central expression of PDE9A closely resembles the 
pattern of the soluble guanylate cyclase, suggesting a cooperation of these two enzymes in 
order to precisely control cGMP levels (Andreeva et al., 2001; Matsuoka et al., 1992). More 
recently and in collaboration with the laboratory of Steven Smith (Orlando), we have shown 
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that PDE9A is also expressed in the AP; this was shown using transcriptome analysis of that 
rat hindbrain (unpublished results). Due to the presence of PDE9A in the AP, and the fact the 
amylin treatment induces a cGMP response in this same region, it seems plausible that 
PDE9A may influence amylin action through the degradation of its second messenger cGMP.   
 
Indeed, sparse, but encouraging, evidence identified PDE9 inhibition as a potential 
therapeutic target for treating diseases from Alzheimer’s to diabetes. The nonselective, 
competitive PDE inhibitor IBMX is not able to inhibit PDE9A, nor are several other PDE 
inhibitors including vinpocetine, rolipram, tadalafil (Wunder et al., 2005). Fortunately, several 
potent and selective inhibitors of PDE9 have been developed in recent years (Deninno et al., 
2009; Kleiman et al., 2012), including the commercially available Bay 73-6691. Bay 73-6691 
is a novel inhibitor, which inhibits specifically the PDE9A with only moderate inhibition of 
the other PDEs (Wunder et al., 2005), and which is thought to have a half-life of 
approximately 2 hours in vitro (van der Staay et al., 2008). Currently Bay 73-6691 is under 
preclinical development against Alzheimer’s disease and also it was shown that it improves 
learning and memory in rats (van der Staay et al., 2008; Wunder et al., 2005).  
 
More recently, Kleiman and colleagues demonstrated, that blockade of PDE9A, by a variety 
of PDE9A inhibitors leads to a dose-dependent accumulation of cGMP. Since cGMP is part 
of multiple downstream neurotransmitter systems, blocking of the degradation by PDE9A 
might yield therapeutic benefits especially in the field of psychiatric and neurodegenerative 
diseases. The findings of Kleiman show that PDE9 inhibition can reverse disruptions of 
working memory by ketamine, or reverse the stereotypic scratching response to mescaline. 
(Kleiman et al., 2012). Furthermore, DeNinno and colleagues described a PDE9-knock out 
mouse which showed reduced weight gain when placed on a HFD, in addition to reduced 
insulin resistance and a lower fat mass (Deninno et al., 2009). These findings show the 
potential importance of the PDE9 modulation for therapeutic benefits.  
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3.6 Can Bay 73-6691 enhance amylin’s anorectic action? 
 
The first half of this dissertation will focus on the potential modulation of amylin action by 
PDE9 inhibition. As previously discussed, amylin induces cGMP formation in the AP 
(Riediger et al., 2001). According to our hypothesis, cGMP is degraded by PDE9A, resulting 
in the termination of amylin’s anorectic effect (Figure 3.1). Hence, we postulated that 
treatment with the PDE9 inhibitor, Bay 73-6691, would slow down the breakdown of cGMP, 
and therefore enhance and prolong amylin’s anorectic action (Figure 3.2). To test this 
hypothesis, several trials were conducted to test how pretreatment with Bay 73-6691, 
administered intraperitoneally, subcutaneously, or directly into the 4th cerebral ventricle, alters 
the feeding response after saline or amylin injection. 
 
Figure 3.1: Working model for the mediation of amylin’s anorectic action: amylin 
induces cGMP, which is broken down by phosphodiesterase 9 to terminate amylin 
action. 
   
16 
 
Figure 3.2: Working model for the mediation of amylin’s anorectic action: if the 
degradation of cGMP were prevented by the PDE9 inhibitor, Bay 73-6691, cGMP would 
be expected to accumulate and amylin signaling may be prolonged.  
 
 
3.7  The role of the AP in amylin-induced restoration of leptin sensitivity  
The second half of the dissertation focuses on whether amylin action in the AP is necessary to 
observe the synergy between amylin and leptin, which is described in detail below.  
 
3.7.1 Leptin 
Leptin is a product of the obese gene (ob) secreted by adipocytes and was first discovered in 
1994 (Zhang et al., 1994). When chronically administered in leptin sensitive individuals either 
centrally or peripherally, leptin reduces body weight through a reduction in food intake and an 
increase in energy expenditure (Halaas et al., 1995; Widdowson et al., 1997). The leptin 
receptor (LepR) is part of the interleukin-6-receptor family (Tartaglia et al., 1995). There are 
multiple isoforms of the LepR, which are produced from a single Lepr gene, and can be 
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divided into three classes: secreted, long and short (Tartaglia, 1997). To produce its effects on 
body weight, leptin binds to the long form of the leptin receptor (LepRb), which results in 
signal transduction via the noncovalently associated tyrosine kinase of the Jak kinase 2 family. 
The activation of Jak2 then phosphorylates and activates signal transducers and activators of 
transcriptions (STATs), in this case STAT3 (Baumann et al., 1996; Ghilardi et al., 1996; Ihle 
and Kerr, 1995). The phosphorylation of STAT3 (pSTAT3) is, therefore, often used as a 
marker of LepRb activation and leptin sensitivity. Based on the localization of LepRb and the 
expression pattern of pSTAT3 following leptin treatment, it is generally assumed that the 
ARH is a primary central target of leptin action (Baskin et al., 1999; Elmquist et al., 1998; 
Hubschle et al., 2001). Other nuclei thought to mediate leptin action include the VMH, the 
dorsomedial nucleus of the hypothalamus, the ventral premamillary nuclei of the 
hypothalamus, the ventral tegmental area, the lateral parabrachial nucleus, and probably also 
the NTS. 
 
 
3.7.2 Leptin resistance in the obese state 
Since its discovery leptin has been studied intensively for its potential as an obesity treatment. 
While leptin reduces body weight in obese, congenitally leptin deficient individuals or rodents 
(Halaas et al., 1995; Licinio et al., 2004), it is typically ineffective in promoting weight loss in 
obese phenotypes that have no defect in leptin production (Knight et al., 2010; Zhang and 
Scarpace, 2006)}. The reason is that obese humans and rodents typically exhibit elevated 
circulating leptin levels, a condition known as hyperleptinemia; unfortunately, this chronic 
increase in leptin concentration cannot prevent overeating and obesity, rather the body 
responds by becoming leptin resistant. Therefore, in most cases of human and animal obesity, 
leptin has little effect, and on its own is often ineffective to treat obesity (Halaas et al., 1995; 
Lin et al., 2000).  
 
While the mechanism underlying leptin resistance is not yet clear, there are several proposed 
causes. One possibility is that leptin transport across the BBB is saturated and leptin no longer 
reaches its receptors in the brain (Banks and Farrell, 2003; Caro et al., 1996). A second 
mechanism may be related to the overstimulation of the LepRb, which then responds with 
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negative feedback signaling (Knight et al., 2010). In support of this theory, increased levels of 
the suppressor of cytokine signaling-3 (SOCS-3), which blocks leptin signaling, have been 
detected in the ARH of leptin-resistant, obese mice (Munzberg et al., 2004). Furthermore, 
heterozygous SOCS-3-deficient mice show greater sensitivity to leptin, with enhanced 
STAT3 signaling, increased weight loss, and protection against diet-induced obesity (DIO) 
(Howard et al., 2004). These results suggest that SOCS-3 might play an important role in 
leptin resistance and, more generally, in the control of leptin sensitivity. 
 
3.7.3 Amylin-Leptin interactions and the role of the AP 
Several lines of evidence demonstrate that combined treatment of amylin and leptin has 
beneficial effects; the most notably being amylin-induced restoration of leptin responsiveness 
in obese humans and rats (Roth et al., 2008). The combination treatment lead to a greater 
body weight loss and inhibition of food intake than would be predicted by mere addition of 
the effects of the individual monotherapies; thus suggesting that amylin and leptin work 
synergistically to produce these effects. This combination treatment also lead to increased 
energy expenditure, where fat was the primary substrate used, rather than carbohydrates 
(Trevaskis et al., 2008). Roth also compared a pair-fed group with the leptin/amylin-treated 
group and could therefore show that the greater efficacy was not only due to the decreased 
food intake elicited by amylin, but that the presence of amylin was actually required for the 
synergistic effect with leptin (Roth et al., 2008) Interestingly, the effect seemed to be specific 
to amylin, as combining leptin with other satiating hormones, like PYY or GLP-1, did not 
produce the same level of fat specific weight loss (Roth et al., 2008). To maintain this weight 
loss, vehicle or leptin treatment seemed to be insufficient, and only further amylin/leptin 
treatment prevented rats from regaining their bodyweight (Trevaskis et al., 2010).  
 
In addition to these effects in rats, a similar synergistic phenomenon was also observed in 
human subjects. Pramlintide, an amylin analogue, produced significant body weight loss and 
food intake reduction when administered alone (Hollander et al., 2004; Smith et al., 2007), 
but the combination treatment of pramlintine and metreleptin was even more powerful (Roth 
et al., 2010). 
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How the interaction of these two hormones is mediated is not yet clear. There is currently no 
evidence that one neuronal population mediates the convergence of these two hormones, and 
it seems more likely that the synergy occurs via an activation of complementary signaling 
pathways. Several studies point towards the VMH as playing a pivotal role in this interaction. 
Most notably, Roth and colleagues showed that amylin can restore leptin responsiveness in 
DIO rats, as further indicated by an increase in pSTAT3 signaling in the VMH (Roth et al., 
2008). While amylin did not restore leptin-induced pSTAT3 in the ARH of DIO rats, chronic, 
peripheral infusion of the two agents lead to an amplified pSTAT3 response in the ARH of 
lean rodents (Turek et al., 2010). Additionally, receptor autoradiography showed that leptin 
binding in the VMH is increased by amylin (Turek et al., 2010), indicating that the VMH 
might play an important role for the convergence of these two satiation hormones.  
The AP is an unlikely primary site of converge for the two hormones, since injections of 
leptin did not enhance the amylin induced c-Fos signaling in this brain region (Turek et al., 
2010). However, it is not clear if activation of the AP by amylin is required for the 
amylin/leptin synergy to manifest, or if amylin interacts with leptin via an alternate pathway. 
In order to determine the role of AP in the leptin/amylin interaction, we attempted to repeat 
the study of Roth and colleagues in DIO rats and extended the study by using rats with or 
without a lesion of the AP. 
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4 Material und Methods 
4.1 Animals and housing conditions  
Male Wistar rats or male Sprague Dawley rats (Elevage Janvier, Le Genest Saint Isle, France) 
were used for all experiments. Upon arrival in our facility, the rats weighed between 225 and 
250 grams. The rats were maintained in a temperature-controlled environment (21 ± 2°C) on a 
12h/12h light-dark cycle. Water and food were accessible ad libitum, unless otherwise 
described. The animals were handled on a daily basis for the first 4 weeks, following which 
they were handled every 1-2 days. Throughout the course of an experiment, bodyweight was 
measured every 2-3 days. Animals were habituated to the housing conditions for at least 7 
days prior to any experimental manipulation. All experiments were approved by the 
Veterinary Office of the Canton of Zürich, Switzerland. 
 
4.1.1 Housing conditions in macrolon cages 
Animals were group-housed in macrolon cages (2-5 rats/cage) prior to undergoing surgery or 
the start of a feeding or immunohistochemical experiment. 
 
4.1.2 Housing conditions in hanging wire mesh-cages 
For most experiments, animals were single-housed in wire mesh cages; two different sizes 
were available and used according to the rats’ body weight: 
23cm x 39cm x 20cm for rats <400g 
47cm x 33cm x 20cm for rats >400g 
Food hoppers were mounted externally to facilitate the manual measurement of food intake. 
 
4.1.3 Housing conditions in the BioDAQ system 
For experiments requiring continuous measurement of food intake, animals were single-
housed in plexiglass Tecniplast cages (Type IV S; 48cm x 38cm x 21cm) fitted with the 
BioDAQ Food Intake Monitoring system (Research Diet Inc., New Brunswick, NJ, USA). 
Environmental temperature and light intensity were measured 24 h per day by the system. The 
BioDAQ system converts the animals’ feeding behavior into data which can be analyzed and 
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stored. Data collected from individual food hoppers were analyzed using the BioDAQ Data 
Viewer, which provides the data in raw format or as graphs and tables. Food hoppers are 
attached to the outside of the cage and rest on a strain gauge that measure the weight of the 
hopper each second; weight changes of the hopper during and after an interaction with an 
animal were converted to eating bouts. If bouts occured one after another within the 
timeframe of the user-specified intermeal interval (15 min), bouts were clustered into meals. 
If the hopper weight remained stable for more than 15 min, the meal was considered 
terminated. These data from the food hopper were permanently stored for further analysis. 
The data could then be analyzed according to the time of the day, the light cycle and 
affiliation to a group. Hence, this system allowed the continuous assessment of total food 
intake, size and number of meals and meal pattern in the dark and light phase, respectively.  
 
 
4.2 Experimental diet 
For most experiments, rats were maintained on a standard rodent chow (Diet 3430; Kliba 
Nafag Provimi Kliba AG, Kaiseraugst, CH). 
Major Nutrients (% per weight): 
 
Dry Matter   88% 
Crude protein 18.5% 
Crude fat 4.5% 
Crude fiber 4.5% 
Crude ash 6.3% 
NfE 54.2% 
Gross Energy 16.1 MJ/kg 
Metabol. Energy 13.2 MJ/kg 
Starch 35.0 % 
Table 4.1.1: Standard Chow from Kliba Nafag 
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In some cases, rats were maintained on a high fat diet (#D12266; Research diets Inc., New 
Brunswick, NJ, USA).  
 
D12266 Formula: 
Product Kcal% 
Protein 16.8 
Carbohydrates 51.4 
Fat 31.8 
Table 4.1.2:  High fat diet from Research diets 
 
 
4.3 Peptides and Drugs 
Amylin (Bachem AG, Bubendorf CH, or Amylin Pharmaceuticals Inc, San Diego, CA, USA) 
was diluted in 0.9% NaCl (Fresenius Kabi AG, Stans, CH) at various concentrations. Leptin 
(Peprotech, Rocky Hill, New Yersey, USA) was diluted at various concentrations in aqua ad 
injectabilia. CCK-8 sulfated (Bachem) was prepared with 0.9% NaCl to a concentration of of 
3 µg/ml. All peptides were prepared immediately before the start of the experiment and were 
kept cold on ice until injection.  
 
For central injection studies the PDE9 inhibitor Bay 73-6691 (Sigma Aldrich, St Louis, MO, 
USA), was diluted in 75% Dimethyl sulfoxide (DMSO; Fluka, Sigma Aldrich) and 25% aqua 
ad injectabilia, and was sonicated for 15 min to promote dissolving (Branson 1200, Bender 
+Hobein, Zürich). When Bay 73-6691 was used for peripheral injection, it was diluted in 20% 
DMSO and 80% aqua ad injectabilia and then treated as described above. 5-Thio-D Glucose 
(Carbosynth) was diluted in 0.9% NaCl to reach a concentration of 210 µg/3 µl. 
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4.4 Surgical techniques 
4.4.1 Cannulation of the 4th cerebral ventricle 
Rats underwent 4th ventricle cannulation under isoflourane anesthesia (Abbott AG, 6341 Baar). 
Anesthesia was induced with 5% isofluorane and was lowered to a maintenance level of 2.5% 
during surgery. One day prior to surgery, rats were treated with Enrofloxacin (Baytril ®; s.c. 
10mg/kg BW; Bayer, Provet SA 3421 Lyssach), and were treated post-operatively with 
Flunixin-meglumin (Flunixin; s.c. 2.5mg/kg BW of 1:50 dilution; Dr. E Graeub AG, CH-
3018 Bern), Baytril, Prednisolon (Prednisolut ®; s.c. 2mg/kg BW; Mibe GmBH 06796 
Brehna), and NaCl (Fresenius Kabi). The antibiotic and the analgesic treatment continued 
until 3 days post-operation.  
 
For implantation of guide cannulas, rats were secured in the stereotactic frame (Stoelting Lab 
Standard Stereotaxic Instrument, Stoelting, IL, USA), and the scalp was shaved and sanitized 
with Braunol. A 2 cm-long incision was made at the midline from cranial to caudal in order to 
visualize Lambda and Bregma. A flat-skull position was achieved by measuring the 
dorsoventral coordinates of Lambda and Bregma, following which the site of cannulation was 
calculated based on the coordinates of Bregma (See Table 4.1.3). Then, a hole for the 4th 
ventricle cannulation was drilled. The coordinates for the 4th ventricle were obtained from the 
stereotaxic brain atlas of Paxinos & Watson (Paxinos and Watson, 1998). Three additional 
holes were made for screws (Stainless steel mounting screws 0-80 x 1/8, length 3.2mm) in a 
radius of 5 mm around the cannulation hole. The screws were implanted as anchor points for 
the dental cement (Technovit 4071; H. Kulzer & Co. GmbH Wehrheim Taunus,BRD) to 
secure the pedestal of the cannula. The guide cannula (22 G C313G/Spc, cut 9mm below ped; 
Plastics One, Roanoke, VA) was lowered to the targeted site, optimally 1.0 mm above the 4th 
ventricle, and was then fixed with dental cement. After the drying of the dental cement, a 
cannula dummy (cannula dummy implant C315DC/SPC, 9mm no projection; Plastics One) 
was inserted, and the skin was sutured with Vicryl 4-0 (Johnson+Johnson Intl, Belgium), if 
necessary. Rats received analgesics and antibiotics for 3 days post-surgery. The coordinates 
for the two cannulation experiments are described with the individual experiments. 
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Figure 4.1: Cannulation of the 4th ventricle 
 
Example for calculated implantation position: 
 
Source Anterior -Posterior Dorsal-Ventral 
Coordinates of Bregma (β) 32.0 47.0 
Distance from β to 4th 
ventricle in atlas 
-11.6 -6.6 
Coordinates for implanting: 20.4 40.4 
Table 4.1.3: Example calculation for cannulation coordinates 
 
 
4.4.1.1 5-Thio-D-Glucose Test 
The 5-thio-D-glucose (5TG) test was performed to verify correct placement of the 4th 
ventricular cannula. Animals were fasted for 3 h before dark onset, and the test began 2 hours 
before dark onset. Baseline blood glucose was determined for each rat and then 5TG (210 
μg/3 μl) was administered slowly in the 4th ventricle by inserting an internal cannula that 
extended 1.5 mm from the guide cannula. Blood glucose was again measured 30 and 60 min 
following the infusion of 5TG. Food was given back at the end of the test. If blood glucose 
increased by a minimum 4.5 mmol/l above baseline, the animal was considered positive and 
correct cannula placement was confirmed (Potes et al., 2012). If a rat was not deemed positive 
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with the 1.5 mm internal cannula, the test was repeated with a 2.0 mm internal cannula. The 
same criteria were applied. 
 
4.4.1.2 Central Injections 
For the 4th ventricular injections Silastic Tubing (ID 0.762 x OD 1.651mm; Tagelswangen, 
Switzerland) was attached to a Hamilton syringe (10 µl, Hamilton Bonaduz AG, Bonaduz, 
CH) and filled with the relevant drug solution, with special care to avoid any air bubbles. 
Prior to filling, the tubing was marked for the volume, which should be delivered (3 µl). The 
free end of the tubing was then attached to the internal cannula (C313I/Spc internal cannula 
fits 9mm guide with 1.5 mm or 2.0 mm proj. and a beveled tip; Plastics One). The dummy 
caps covering the guide cannulas were removed and the internal cannula carefully inserted. A 
volume of 3 µl was then slowly and carefully infused. After the volume was delivered, the 
internal cannula was left in place for 1-2 min before removal, to prevent backflow of the 
infusate out of the cannula. 
 
4.4.2 Area postrema lesion 
Animals underwent area postrema lesion (APX) surgery under a mixture of ketamine 
(100mg/kg; Narketan, Vetoquinol) and xylazine (5mg/kg; Streuli Ag, Uznach) anesthesia. 
Vitamin A ointment (Bausch & Laub Swiss AG) was applied generously to the eyes to 
prevent dry eyes. The scalp was shaved and sanitized with Braunol. Animals were placed in a 
stereotactic frame, and fixation of the head was made with the help of the ear bars and the 
nosepiece, which pressed the head down in order to visualize the crista occipitalis. A 1.5 cm 
long vertical incision with the scalpel was made from 0.5 mm above to 1 cm below the crista 
occipitalis and the first layer of muscles were cut. The second and third layer of muscles were 
bluntly dissected in order to visualize the atlanto-occipital membrane. A T-shaped cut was 
made directly under the crista occipitalis in the dura membrane, and if the membrane was 
obstructing the view, it was carefully removed with a bent needle. The area postrema was 
then aspirated by vacuum sucking using a blunted 26 G needle. After verifying the absence of 
the area postrema visually, the wound was sutured with Vicryl 4-0. Flunixin, prednisolone 
and saline were administered post-operatively as indicated above. Post-surgical treatment 
with painkillers and antibiotics continued for three days or longer if indicated. The protocol 
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for the APX was modified from the thermal area postream lesions performed by Mc Glone 
and colleaques (McGlone et al., 1980). 
 
 
4.5  Conditioned Taste Aversion 
Wistar rats were subjected to the conditioned taste aversion protocol outlined below, based on 
the paradigm used by le Roux (le Roux et al., 2011). Rats were fluid deprived for 19.25 hours 
followed by 30 min access to water or saccharine (0.3%); saccharine was given only the first 
30 min of fluid access on conditioning days, while water was given in all other occasions. 
After an additional fluid deprivation of 3.5 h rats had again access to water for 45 min. 
Following saccharine access on conditioning days (day 6, 9 and 12), rats received one of the 
following intraperitonal injections: vehicle, Bay 73-6691 (0.1mg/kg) or lithium chloride. On 
experimental day 14, rats were given access to both water and saccharine for 30 minutes and 
the respective amounts consumed were recorded. 
 
 
Figure 4.2: Conditioned Taste Aversion schedule 
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4.6 Implantation of minipumps 
On the day of implantation, minipumps (Alzet, osmotic minipumps model 2002, Charles 
River; Wilmington MA, USA) were weighed and the empty weight was noted. Half of the 
minipumps were filled with the experimental peptide or drug solution, and the other half filled 
with the appropriate vehicle. To fill the pumps, a 1-ml syringe (Omnifix, Braun; Melsungen, 
GE) was fixed to an injector, which was delivered together with the minipumps. After the 
filling the weight of the pump was measured again to verify that the pump was correctly and 
completely filled (mean filling volume: 213 µl). Prior to implantation, the pumps were placed 
in a container of sterile saline. If the minipump was attached to a saline filled tube, priming 
was needed, which was done by placing the minipump in a container with sterile, 37°C-warm 
saline. In this environment, which resembles the body fluid environment and temperature 
after implantation, the pump started delivering the drug, replacing the saline in the tube with 
the drug solution. After the priming the pump could be used directly, delivering the desired 
substance immidiately after implantation. 
 
4.7 Perfusions protocol and Immunohistochemistry 
Two perfusion protocols were used for detecting c-Fos or pSTAT3, respectively, in rat brain 
tissue. 
 
4.7.1 Perfusion protocol for detection of neuronal marker c-Fos 
Animals were injected with pentobarbital (60mg/kg; Kantonsapotheke Zürich) and perfused 
intracardially (100 ml/min) with 0.1 M phosphate buffer (PB) solution for 90 seconds, 
followed by ice cold 4% paraformaldehyde (Sigma- Aldrich, pH 7.2) in 0.1 M PB for 120 
seconds. After this procedure, the brains were removed and post-fixed in 4% 
paraformaldehyde solution for 2 hours, followed by 48 hours cryoprotection in 20% 
sucrose/PB solution.  
 
0.1 M Sodium phosphate buffer (PB) preparation: 
3000 ml dH20 
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32.8 g Sodium phosphate dibasic dehydrate (Sigma Aldrich Steinheim) 
12.68 g Sodium phosphate monobasic monohydrate (Sigma Aldrich Steinheim) 
Adjust pH to 7.4 with NaOH 
 
4% Paraformaldehyde solution: 
1000 ml dH20 
80 g Paraformaldehyde (Sigma Aldrich Schnelldorf, Germany) 
1000 ml 0.2 M PB  
Drops of NaOH 
Adjust pH to 7.2 with Hcl 
 
4.7.2 Perfusion for detection of neuronal marker p-STAT3 
The animals were injected with pentobarbital as indicated above and perfused intracardially 
(100 ml/min) with 0.9% NaCl solution for 90 seconds, followed by ice cold 2% 
paraformaldehyde (Sigma-Aldrich, pH 7.2) in potassium-phosphate-buffered saline (KBPS) 
for 120 seconds. After this procedure the brains were removed and post-fixed in 2% 
paraformaldehyde solution for 2 hours, followed by 48 hours cryoprotection in 20% 
Sucrose/KBPS solution.  
 
KPBS (0.02 M): 
9.7 g KH2PO4 
56.6 g K2HPO4 
178.2g NaCl 
 
2% Paraformaldehyde solution: 
1000 ml dH20 
40 g Paraformaldehyde (Sigma Aldrich Schnelldorf, Germany) 
1000 ml 0.2 M PB  
Drops of NaOH 
Adjust pH to 7.2 
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4.7.3 Brain tissue processing 
The brains were frozen in chilled hexane (Fluka Chemie GmbH, Buchs SG, CH) on dry ice, 
and stored at -20°C until sectioned coronally using a cryostat (Leica CM3050S, Nussloch, 
Germany). Twenty-micrometer sections collected from the hindbrain (containing AP and 
NTS; according to Paxinos and Watson, 2007) were thaw mounted onto adhesion glass slides 
(Superfrost Plus, Gerhard Menzel GmbH, Braunschweig, Germany). 
If brain sections were stained using free-floating immunohistochemistry, sections were cut 30 
µm thick and stored in cryoprotectant at -20°C until staining.  
 
Cryoprotectant: 
50% 0.1M PB 
30% ethylene glycol 
20% glycerol 
 
4.7.4 Gelatinizing Slides 
Solution: 
1.5 g Gelatin, type A, 220 or 275 Bloom     
0.25 g Chromium potassium sulfate               
500 ml Distilled water  
                                         
Water was heated to 60°C to dissolve all substances, then glass slides (Thermo scientific, 
Menzel Gläser geschnitten) were dipped 3-4 times in the gelatinizing solution and left to air 
dry. 
 
4.7.5 c-Fos Immunohistochemistry 
The c-Fos immunohistochemistry was performed in free-floating brain sections. Sections 
were washed 2 x 5 min with 0.1 M PB to rinse off cryoprotectant. Sections were incubated in 
0.5% H2O2 in dH2O for 10 min to quench endogenous peroxidase, followed by 3 x 10 min 
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washing in 0.1 M PB. Sections were blocked for 1 h in 0.1 M PB containing 0.3% Triton X-
100 (PBTX) and 1% normal goat serum (NGS), followed by an overnight incubation in 
polyclonal rabbit anti-c-Fos (1:10,000 in 0.3% PBTX and 1% NGS; AB-5, Oncogene from 
Calbiochem) at room temperature. Sections were washed three times in 0.1% PBTX, and 
were then incubated for 1 h in biotinylated goat-anti-rabbit secondary antibody (1:400 in 0.3% 
PBTX; Jackson ImmunoReaseach, Inc). Sections were washed 3 x 10 min in 0.1% PBTX and 
then incubated for 1 h in avidin-biotin-peroxidase complex (1:500 in 0.3% PBTX; Vectastain 
ABC kit, Vector). After additional washing steps (2 x 10 min) in 0.1% PBTX, sections were 
incubated in 3,3’-Diaminobenzidine Tetrahydrochloride (DAB, Sigma) solution for 3 to 4 min 
to visualize c-Fos-positive cells. The DAB solution was prepared as follows: 2.5 mg DAB per 
10 ml 0.1 M PB and 50 µl H202. Sections were then rinsed, mounted on gelatinized slides, 
dehydrated through an ascending series of alcohols, cleared with xylol, and coverslipped.  
 
4.7.6 pSTAT3 Immunohistochemistry 
Slides were first dried for one hour at room temperature, then rinsed in 0.02 M KPBS (2 x 5 
min). All rinsing steps were done in 0.02 M KPBS. For demasking, the slides were incubated 
20 min at room temperature in 0.3% NaOH (Sigma Aldrich 5M) and 0.3% H2O2 (Sigma 
Aldrich, Steinheim) in KPBS. Demasking is necessary for making a masked substance 
capable of undergoing reactions. Slides were again rinsed in KPBS (8 x 5 min), followed by a 
10 min incubation with 0.3% Glycine (Fluka/Sigma Aldrich Chemie, Buchs, Switzerland) in 
KPBS. The slides were rinsed before being demasked a second time for 10 min in a 0.03% 
sodium lauryl sulfate (Carl Roth GmBH, Karslruhe, Germany) in KPBS solution. To block 
unspecific antibody binding, slides were incubated for 20 min in a blocking solution of 4% 
normal donkey serum (NDS; Jackson Immuno Research), 0.4% Triton X 100 (Sigma Aldrich), 
and 1% bovine serum albumin in KPBS. Following a washing step, the slides were then 
incubated with the primary antibody (1:500, Phospho-Stat3 XPTM Rabbit mAb #9145, Cell 
Signaling Technology Inc., Denver MA, US) in 1% NDS, 0.4% Triton, 1% BSA in KPBS for 
48 h at 4 °C. After washing (8 x 5 min), slides were incubated with the secondary antibody 
(1:100, donkey anti-Rabbit Alexa-555 IgG (H+L), Invitrogen AG, Basel, CH) in 1% NDS and 
0.3 % triton in KPBS for 120 min at room temperature. After a final washing step (8 x 5 min) 
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the slides were covered with Citifluor (Glycerol/PBS solution Citifluor Ltd., London) and 
cover slipped.  
 
 
4.8 Description of individual experiments 
4.8.1 Effect of central administration of Bay 73-6691 on the action of peripheral 
amylin 
4.8.1.1 Experiment 1a 
Bolus central infusion of Bay 73-6691 with 10 μg/3 μl 
 
Wistar rats (n=36, starting body weight of 225-250 grams; Janvier) underwent 4th ventricular 
cannulation surgery as described above. The following stereotaxic coordinates were used: 
anterior-posterior -11.6 dorsal-ventral -6.6, on the midline (Brain Atlas Paxinos & Watson 
1998). Rats were allowed to recover for 7 days, after which correct cannula placement was 
tested using the 5TG test. Twenty-one animals had an increase of blood glucose higher than 
4.5 mmol and were therefore included in the study. 
 
On test days, food was removed 2.5 hours prior to dark onset, and 1.5 hours prior to dark 
onset 3 μl of vehicle or Bay 73-6691 (10 μg) was slowly infused in the 4th ventricle. Saline or 
amylin (5 μg/kg) was given intraperitoneally 15 min before dark onset. Food was returned at 
dark onset and the food intake was measured manually at 1, 2, 4 and 24 hours. The study was 
performed as a four-time crossover so that each animal was tested under each condition 
(veh/NaCl; Bay 73-6691/NaCl; veh/amylin; Bay 73-6691/amylin). 
 
4.8.1.2 Experiment 1b 
Bolus central infusion of Bay 73-6691 with 20 μg/3 μl 
 
The study design matched that described above in experiment 1a, but the dose of Bay 73-6691 
was increased to 20 μg Bay 73-6691 dissolved in 3 μl vehicle. A two-time crossover was 
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performed so that each animal was tested under two conditions. One group received veh/NaCl 
and veh/amylin, while the other group received Bay73-6691/amylin and Bay73-6691/NaCl.  
 
4.8.1.3 Experiment 1c 
Bolus central infusion of Bay 73-6691 with a 3 hours delay  
 
To test an alternate time window of Bay 73-6691 action, experiment 1b was repeated, 
however the time interval between the Bay 73-6691 infusion and the amylin injection was 
increased. Food was removed 4 h prior to dark onset, and vehicle or Bay 73-6691 (20 μg/3 μl) 
was slowly infused into the 4th ventricle 3 h before dark onset. Saline or amylin (5 μg/kg) 
was given intraperitoneally 15 min before dark onset, and food intake was measured as 
described above. 
 
4.8.1.4 Experiment 1d 
Effect of chronic central infusion of Bay 73-6691 on amylin action  
 
Due to inconlusive results and the assumption that this strain of Wistar rats showed only low 
sensitivity to amylin, we used Sprague Dawley rats (n=30, starting BW 225- 250 grams; 
Janvier), which underwent 4th ventricular cannulation surgery as described above. The 
following stereotaxic coordinates were used: anterior-posterior -11.6 dorsal-ventral -7.2, on 
the midline (Brain Atlas Paxinos & Watson 1998). Rats were allowed 7 days to recover, after 
which correct cannula placement was tested using the 5TG test. Twenty-two animals had an 
increase of blood glucose higher than 4.5 mmol and were therefore included in the study. 
Coordinates differed from those used in Experiments 1a-d, because this experiment required a 
different guide cannula (Guide Combination for rats 326OPG/SP Plastic Ones, Op Connector), 
to which a minipump could be attached.  
 
Eleven animals received a minipump filled with Bay 73-6691, which was placed 
subcutaneously between the scapulae and connected by a vinyl catheter tubing (Durect, 
Product od Durect Corp, Cupertina CA) to the guide cannula. The pumping rate was 6.66 
μg/h which was delivered directly into the 4th ventricle. Nine animals received minipumps 
   
33 
infusing vehicle. After recovery, rats were transferred to the BioDAQ System in order to 
continually monitor food intake. Following acclimatization to the new environment, a two-
times crossover was performed. On test days, animals were fasted for 2.5 h prior to dark onset, 
saline or amylin (5 μg/kg; Amylin Pharmaceuticals) were given subcutaneously 15 min prior 
to dark onset, and then access to food was allowed. Food intake was then continuously 
measured by the system. 
 
4.8.1.5 Experiment 1e 
Activation of c-Fos following chronic central infusion of BAY 73-6691 
 
In a final experiment, rats used in experiment 1d were food deprived for 2.5 h and shortly 
before dark onset either vehicle or amylin (5 μg/kg) was injected. Food was not given back 
and animals were perfused after 1.5 h according to the c-Fos perfusion protocol described 
above. Brains were processed for free floating c-Fos staining. 
 
 
4.8.2 Effect of peripheral administration of Bay 73-6691 on amylin action 
4.8.2.1 Experiment 2a 
Peripheral administration of Bay 73-6691 
 
Wistar rats (n=20 starting body weight of 225-250 grams; Janvier) were fasted 2.5 h before 
dark onset and food was weighed. Bay 73-6691 (1 mg/kg; i.p.) or vehicle (80% aqua 
injectabila and 20% DMSO) was injected 1.5 hours prior to dark onset. Saline or amylin (5 
μg/kg; i.p.) was given 15 min before dark onset. Food was returned at dark onset and the food 
intake was measured manually at 1, 2, 4 and 24 hours. The study was performed as a four-
time crossover. 
 
Due to inconclusive results the experiment was repeated with different parameters: the rat 
strain was changed to Sprague Dawley, amylin was used from another source (Amylin 
Pharmaceuticals) and was administered s.c., the amount of DMSO in the vehicle solution was 
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decreased to 10% and the fasting time was prolonged to six hours. Despite changing these 
different factors, the outcome of the experiment remained unchanged.  
 
4.8.2.2  Experiment 2b 
Conditioned Taste Aversion (CTA) 
 
Wistar rats (n=20, Janvier) underwent a conditioned taste aversion test to determine if Bay 
73-6691 induces malaise that may lead to a reduction in eating and hence could mask an 
effect of the PDE inhibitor to increase amylin’s anorectic effect. The 14-day protocol outlined 
above was used. Rats were subjected to conditioning days, in which they had only limited 
access to water (1 x 30 min; 1 x 45 min); the rest of the time they were water deprived. On 
conditioning days, rats had first 30 min access to saccharine followed by an injection of either 
vehicle, Bay 73-6691 or lithium chloride which was used as a positive control (Nachman and 
Ashe, 1973), followed by 45 min access to water. On the final test day, rats were given the 
choice to drink water or saccharine. 
 
4.8.2.3 Experiment 2c 
Sensitivity to amylin as assessed by c-Fos activation  
 
This study was performed to determine the rat’s sensitivity to amylin, as the results of 
experiment 2a suggested a reduced sensitivity of the rat strain used here. Therefore 20 Wistar 
rats from Janvier were fasted for 2.5 h, and 15 min before dark onset the animals received 5 
μg/kg amylin (n=5), 20 μg/kg amylin (n=5), 50 μg/kg (n=4), CCK 3 μg/kg (n=1) or Saline 
(n=5). Food was not given back after injection and after 1.5 h, animals were perfused 
according to the c-Fos perfusion protocol above. Sections of brains were stained for c-Fos to 
determine the extent of neuronal activation following amylin administration. CCK, known to 
produce a robust c-Fos response in the AP and NTS, was used as a positive control. From 
each rat, five brain sections from the same anatomical level containing the AP/NTS were 
photographed using the Zeiss AX10Imager.Z2 microscope. The number of c-fos positive cells 
was estimated in a semiquantitative way. 
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Some of the experiments yielded unexpected results and therefore different attempts were 
made to improve amylin sensitivity: the strain of rats was changed, route of administration 
and also the source of amylin. However, as long as Bay 73-6691 or its vehicle was 
administered before amylin, no effect of amylin on eating was observed.  
Hence, on two occasions, amylin action was tested in the absence of Bay 73-6691 or its 
vehicle. Rats were fasted for 2.5 h, and 15 min before dark onset amylin was injected (5 µg/kg; 
i.p.), and food intake was measured 1, 2, and 4 hours later. 
 
 
4.8.3 The role of the AP in the amylin-induced restoration of leptin sensitivity  
4.8.3.1 Experiment 3a 
Area postrema lesion and area postrema lesion verification test 
 
Sprague Dawley rats (n=50, Charles River Laboratories International Inc. Wilmington US) 
were given 2 weeks ad libitum access to high fat diet (HFD) and, based on the percentage of 
weight gain on this diet, rats were then separated into diet induced obesity (DIO; n=33) and 
diet resistant (DR) groups. Weight gain over 30 % of the original BW was considered DIO, 
DR rats gained less than 30%. The DIO rats were maintained on the HFD for a total of 8 
weeks, and were transitioned back to standard chow at the time of minipump implantation 
(see below). The DIO rats were then randomly assigned to the area postrema lesion (APX; 
n=14) or the sham operated group (n=11). Following recovery, an area postrema lesion 
verification test was performed. Rats were fasted for 2 hours, and immediately before dark 
onset, either saline or amylin (5 μg/kg) was injected. Food was given back at dark onset and 
food intake measured at 1,2 h and 4 h time points. Animals with complete area postrema 
lesions should not eat less after administration of amylin, and rats showing a reduction in food 
intake of 15% or greater were omitted from the study because their lesion was considered 
incomplete. The test was performed as a two-time crossover. Correct lesions of the area 
postrema were confirmed by this functional test (n=11), and again at the end of the 
experiment through histology. 
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4.8.3.2 Experiment 3b 
Effect of chronic peripheral infusion of amylin on body weight 
 
Alzet minipumps were purchased from Charles River and filled according to the 
manufacture’s protocol; the pumps were filled with amylin (100 μg/kg/day) or with saline. 
The four groups of animals were as follows: sham + saline minipump (n=6); sham + amylin 
minipump (n=7); APX + saline minipump (n=4); APX + amylin minipump (n=6). The 
minipumps delivered infusates for approximately 14 days.  
 
4.8.3.3 Experiment 3c 
Effect of amylin infusion on leptin-induced anorexia  
 
After approximately one week of amylin or saline infusion, leptin-induced anorexia was 
assessed in DIO rats with or without an AP lesion. Food was removed 2 h before dark onset 
and either vehicle or leptin (5 mg/kg; i.p.) was injected. Food was given back at dark onset 
and the amount consumed was measured at 4 h and 24 h post-injection. The trial was 
designed as a two-time crossover.  
 
4.8.3.4 Experiment 3d 
Effect of amylin infusion on leptin-induced STAT3 phosphorylation 
 
The role of the AP in the amylin-induced restoration of leptin sensitivity was again tested in a 
terminal experiment, in which the leptin-induced phosphorylation of STAT3 was determined 
in sham or AP-lesioned DIO rats. Thus, on day 13 following the minipump implantation the 
final trial was performed as follows: Food was removed 2 h before dark onset and at dark 
onset the animals received either vehicle or leptin (5 mg/kg). Forty-five min after the 
injections the perfusion was performed according to the pSTAT3 perfusion protocol described 
above. Brains were then cut and stained for pSTAT3. From each rat, five brain sections from 
approximately the same anatomical level containing the VMH were photographed using the 
Zeiss AX10Imager.Z2 microscope. To quantify the number of pSTAT3-positive cells, the 
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grayscale images were inverted using Adobe Photoshop, positive cells were manually counted, 
and the average across the five sections was calculated. 
 
4.9 Statistics 
All data are presented as mean ± SEM, and were considered significant with a p-value of 
<0.05. Statistical analyses were done with the program Prism version 5.0 for Mac OS X 
(Graph Pad Software Inc. San Diego, USA). Crossover data was anlyzed using a two-way 
Anova with Bonferroni post-hoc test. When only two groups were compared, a Student’s t-
test was used for analysis. 
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5 Results 
5.1 Effect of central administration of Bay 73-6691 on the action of peripheral amylin 
5.1.1 Results of Experiment 1a  
Bolus central infusion of Bay 73-6691 with 10 μg/3 μl 
 
To test if Bay 73-6691 enhances the eating inhibitory effect of amylin, rats were pretreated 
with 10 μg Bay 73-6691 injected into the 4th ventricle, followed by peripheral treatment of 
amylin just before dark onset 
 
Figure 5.1: Mean ± SEM food intake 1 (A), 2 (B), and 4 h (C) after dark onset in rats 
pretreated with 4th ventricular vehicle or Bay 73-6691 (10 μg) 1.5 h before dark onset, 
followed by an injection of saline (white bars) or amylin (5 μg/kg i.p., black bars) 
immediately before dark onset. Symbols denote significant individual differences 
compared to the respective control group; **p<0.01, *p<0.05. 
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A significant reduction of food intake occurred in the animals which received vehicle and 
amylin treatment, in comparison to those treated with vehicle and saline. Food intake was 
decreased in the first hour by approximately 40%. Surprisingly, in the group which was 
pretreated with Bay 73-6691, amylin did not change food intake compared to saline control 
animals, and both groups seemed to have a tendency to eat less than the vehicle-saline control 
group (Fig. 5.1A). The reduction of food intake in the animals treated with vehicle-amylin 
was still visible after 2 hours (Fig. 5.1B), while 4 hours post-injection no significant effect 
was observed (Fig. 5.1C). 
 
 
 
5.1.2 Results of Experiment 1b  
Bolus central infusion of Bay 73-6691 with 20 μg/3 μl 
 
As we did not observe an increased anorectic effect of amylin after Bay 73-6691 treatment in 
the first experiment, the dose of Bay 73-6691 was increased to 20 μg per infusion for the 
second experiment. Figure 5.2A demonstrates that in the first hour, there was an approximate 
50% decrease of food intake in animals which received the vehicle-amylin treatment in 
comparison to the group receiving vehicle-saline (p=0.01). In the group receiving Bay 73-
6691 pretreatment, we observed a tendency for amylin to decrease food intake, though this 
effect was not significant. In the second hour (Fig. 5.2B), there was a tendency for amylin to 
reduce food intake in both vehicle- and Bay 73-6691-treated groups. Four hours following 
dark onset (Fig. 5.2C), peripheral amylin significantly reduced food intake (p<0.01) in rats 
pretreated with Bay 73-6691. A similar trend was also present in the vehicle group, however 
the effect was not significant.  
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Figure 5.2: Mean ± SEM food intake 1 (A), 2 (B), and 4 h (C) after dark onset of rats 
pretreated with 4th ventricular vehicle or Bay 73-6691 (20 μg) 1.5 h before dark onset, 
followed by an injection of saline (white bars) or amylin (5 μg/kg i.p., black bars) 
immediately before dark onset. Symbols denote significant individual differences; 
**p<0.01, ***p<0.001. 
 
 
5.1.3 Results of Experiment 1c 
Bolus central infusion of Bay 73-6691 with a longer (3-hour) delay between Bay 73-6691 and 
amylin administration  
 
Results from Experiment 1b suggested that Bay 73-6691 enhanced amylin action relatively 
late, i.e. only four hours after amylin administration, when a prolongation of amylin’s 
anorexic effect was observed. Based on these results, in the third experiment, food was 
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removed 4 h prior to dark onset and Bay 73-6691 was infused into the 4th ventricle 3 h before 
dark onset at a dose of 20 μg/3 μl. As before, saline or amylin was given intraperitoneally 15 
min before dark onset. As shown in Figure 5.3A, in the groups pretreated with vehicle, amylin 
treatment produced a significant decrease in food intake after one hour (p<0.05). Two and 
four hours after dark onset (Figs. 5.3B and 5.3C), amylin still had a tendency to reduce food 
intake in vehicle-pretreated groups, but this effect was no longer significant. There was no 
effect of amylin in rats pretreated with Bay 73-6691 at any time.  
 
  
 
Figure 5.3: Mean ± SEM food intake 1 (A), 2 (B), and 4 h (C) after dark onset of rats 
pretreated with 4th ventricular vehicle or Bay 73-6691 (20 μg) 3.0 h before dark onset, 
followed by an injection of saline (white bars) or amylin (5 μg/kg i.p., black bars) 
immediately before dark onset. Symbols denote significant individual differences;  
*p<0.05. 
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5.1.4 Results of Experiment 1d 
Effect of chronic central infusion of Bay 73-6691 on amylin action  
 
Animals underwent a 4th ventricle cannulation surgery and were then implanted with 
minipumps. The minipumps were either filled with vehicle or Bay 73-6691, and released Bay 
73-6691 at a dose of 6.66 μg/h (0.5 μl/h) for 14 days.  Following implantation, rats were 
housed in BioDAQ® cages, which allowed us to continuously measure food intake. On test 
days (day 2 and 4), rats were fasted 2.5 hours before dark onset, and 15 min before dark onset, 
rats received saline or amylin (5 μg/kg s.c.).Food access was then given at dark onset. During 
the first two hours after dark onset (Figs. 5.4A and 5.4B), we observed that amylin had a clear 
tendency to reduce food intake in both groups of animals. 
 
 
Figure 5.4: Mean ± SEM food intake 1 (A), 2 (B), 4 (C) and 5 h(D) after dark onset of 
rats with 4th ventricular chronic infusion of Bay 73-6691 (6.66 μg/h) or vehicle, followed 
by an injection of saline (white bars) or amylin (5 μg/kg i.p., black bars) immediately 
before dark onset. 
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There was no additional reduction of food intake in rats treated with the combination of 
chronic Bay 73-6691 and acute amylin compared to the vehicle-amylin group. Amylin’s 
tendency to reduce food intake remained in the fourth hour (Fig. 5.4C) in the vehicle-treated 
group, but not in the Bay 73-6691-treated group. By the fifth hour after injection (Fig. 5.4D), 
there were no differences in food intake across groups 
 
 
 
 
Analyses of meal patterns during chronic central infusion of BAY 73-6691  
 
To assess if despite the lack of effect on cumulative food intake, chronic central infusion of 
Bay 73-6691 influenced baseline meal patterns, two non-test days were used to analyze 
feeding behavior, i.e. total 24h-food intake, average number of meals, average size of first and 
second meal, average latency to first meal, and average intermeal interval. Compared to 
vehicle-infused rats, chronic central infusion of Bay 73-6691 had no effect on the baseline 
number of daily meals (Fig. 5.5A), total daily food intake (Fig. 5.5B), size of first meal (Fig. 
5.5C), size of second meal (Fig. 5.5D), nor the average length of the intermeal interval (Fig. 
5.5F). Figure 5.5E demonstrates a slight tendency for Bay 73-6691 to decrease the latency to 
the first meal, compared to rats with chronic infusion of vehicle, but this effect was not 
significant.  
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Figure 5.5: Mean ± SEM number of meals (A), total daily food intake (B), size of first 
meal (C), size of second meal (D), latency to the first meal (E), and intermeal interval (F) 
on a non-test day of rats with 4th ventricular chronic infusion of vehicle (white bars) or 
Bay 73-6691 (6.66 μg/h, black bars).  
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5.1.5 Results of Experiment 1e 
Activation of c-Fos following chronic central infusion of Bay 73-6691 
 
To assess if chronic central treatment with Bay 73-6691 enhanced the amylin-induced c-Fos 
formation, rats fitted with minipumps infusing vehicle or Bay 73-6691 were food deprived for 
2.5 hours and shortly before dark onset received either vehicle or amylin (5 μg/kg; s.c.). Food 
was not returned, and 90 min later rats were perfused according to the c-Fos perfusion 
protocol described above. The brains were processed for free floating immunohistochemistry 
and stained against c-Fos. Figure 5.6 depicts the quantification of c-Fos positive cells in the 
area postrema. Amylin induced a slight, though not significant, increase in the number of c-
Fos positive cells in rats chronically infused with vehicle. In rats treated chronically with 
central Bay 73-6691, there was a significant increase of c-Fos in the area postrema. 
Representative images of c-Fos labeling in the area postrema are shown in Figure 5.7. 
 
 
Figure 5.6: Male Sprague Dawley rats underwent 4th ventricle cannulation surgery and 
minipump implantation, loaded with Bay 73-6691 (6.66 μg/h) or vehicle, followed by an 
injection of saline (white bars) or amylin (5 μg/kg s.c., black bars) just before dark onset. 
Animals were perfused 1.5 h afterwards. C-Fos positive cells in the AP were counted. 
Symbols denote significant individual differences;  *p<0.05.  
 
N
o.
 o
f c
-fo
s 
po
s.
 c
el
ls
Ve
h Ba
y
0
10
20
30
Saline
Amylin
_____*
   
46 
 
 
 
Figure 5.7: Representative brightfield photomicrographs showing c-Fos 
immunoreactivity in the area postrema 90 min after treatment with vehicle-saline (A), 
Bay 73-6691-saline (B), vehicle-amylin (C) and Bay 73-6691-amylin (D). Scale bar = 200 
µm 
 
 
5.2 Effect of peripheral administration of Bay 73-6691 on amylin action 
5.2.1 Results of Experiment 2a 
Peripheral administration of Bay 73-6691 
 
To assess if peripheral administration of Bay 73-6691 enhances amylin’s anorectic action, rats 
were pretreated peripherally with either vehicle or Bay 73-6691 (0.1 mg/kg; i.p.) 1.5 hours 
before dark onset, followed by treatment with saline or amylin (5 μg/kg; i.p.) shortly before 
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dark onset. Figure 5.8A shows that there was no difference in food intake between vehicle-
treated rats which received saline or amylin. In the group which received Bay 73-6691, 
amylin had a tendency to reduce food intake, though this effect was not significant. Similar 
results were observed two hours (Fig. 5.8B), and four hours after dark onset (Fig. 5.8C); i.e., 
there were no differences in food intake across all groups.  
 
 
  
 
Figure 5.8: Mean ± SEM food intake 1 (A), 2 (B), and 4 h (C) after dark onset of rats 
pretreated vehicle or Bay 73-6691 (i.p.; 0.1 mg/kg) 1.5 h before dark onset, followed by 
an injection of saline (white bars) or amylin (5 μg/kg;black bars) immediately before 
dark onset.  
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5.2.2 Results of Experiment 2b 
Conditioned Taste Aversion (CTA) 
 
Under some conditions, Bay 73-6691 appeared to reduce food intake compared to vehicle-
saline treated rats, i.e. even in the absence of amylin. We therefore tested if peripheral 
administration of Bay 73-6691 itself may affect eating, possibly by the induction of a 
condition taste aversion. Rats were trained under the CTA paradigm described previously (le 
Roux et al., 2011); on the final test day, rats were offered a choice of water or saccharine; this 
allowed us to determine if Bay 73-6691 induced feelings of malaise in rats. Figure 5.9 shows 
that on the final test day, regardless of treatment with vehicle or Bay 73-6691, all rats showed 
a significant preference to drink saccharine versus water during a 30 min test, indicating that 
there was no evidence for BAY 73-6691 to induce a CTA. 
 
Figure 5.9: Mean ± SEM intake of water (white bars) and saccharine (black bars) 
during the final 30 min test of the CTA paradigm in rats treated with vehicle or Bay 73-
6691. Symbols denote significant differences between water and saccharine intake;  
***p<0.001. 
 
5.2.3 Results of Experiment 2c 
Sensitivity to amylin as assessed by c-Fos activation 
 
A critical component of every experiment in this part of the dissertation was a reliable and 
robust anorectic effect of amylin. Unfortunately and unexpectedly, this effect was rarely 
observed. To assess the rats’ sensitivity to amylin, various doses of amylin were injected 
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peripherally, and the accumulation of c-Fos, a marker of neuronal activation, was semi-
quantified in the area postrema to determine if the rats responded to amylin. CCK-induced c-
Fos was used as a positive control. Rats were fasted 2.5 hours before dark onset and shortly 
before dark onset injected with either saline, amylin (5 μg/kg, 20 μg/kg, or 50 μg/kg) or CCK 
(3 μg/kg). Rats were perfused 90 min later and the hindbrains were processed for c-Fos 
immunohistochemistry. The number of c-Fos positive cells was estimated in a 
semiquantitative way, using the following evaluation of c-Fos cells: 
- = <10 positive cells 
+ = 10 positive cells 
++ = 20 positive cells 
+++ = 30 positive cells 
 
 Treatment  c-Fos signaling 
 Saline  -  
 Amylin 5 μg/kg  + 
 Amylin 20 μg/kg  - 
 Amylin 50 μg/kg  +++ 
 CCK 3 μg/kg  +++ 
 
Table 5.1.1: Semi-quantification of c-Fos positive cells in area postrema slices. 
 
Figure 5.10A shows a representative rat that received saline, which resulted in c-Fos 
activation in just a few cells. Figures 5.10B, C, and D depict representative brain sections of 
rats treated with increasing doses of amylin. Only animals treated with the highest dose of 
amylin (50 μg/kg) showed a clear c-Fos response in the AP. A CCK-treated rat is depicted in 
Figure 5.10E; this comparably low dose resulted in the most robust c-Fos response of all 
treatment groups. Hence, for reasons that are unknown to us, the rat strain used in these 
experiments seemed to be relatively insensitive to the actions of amylin when compared to 
previous studies where amylin appeared to be more potent than CCK when given at 
comparable doses (Lutz et al., 1998; Reidelberger et al., 2001; Young et al., 1996). 
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Figure  5.10: Representative brightfield photomicrographs showing c-Fos 
immunoreactivity in the area postrema 90 min after treatment with saline (A), 5 μg/kg 
amylin (B), 20 μg/kg amylin (C), 50 μg/kg amylin (D), or 3 μg/kg CCK (E). Scale bar = 
200 µm 
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5.3 The role of the AP in amylin-induced restoration of leptin sensitivity  
5.3.1 Identification of DIO and DR rats after HFD 
Rats were maintained on a HFD for 8 weeks before the area postrema lesions were performed. 
After two weeks on HFD, rats were designated diet-induced-obese (DIO) or diet-resistant 
(DR) according to their body weight gain (Fig. 5.11). For the purpose of this study, rats 
gaining over 30% of the initial BW in these two weeks were considered DIO, while those 
gaining less than 30% were designated DR.  
 
 
  
Figure 5.11: Body weight gain of the DR (empty circles) and DIO rats (black squares) 
maintained on HFD from week 1. Symbols denote significant individual differences 
between groups;  *p<0.05; **p<0.01; ***p<0.001. 
 
 
5.3.2 Results of Experiment 3a 
Area postrema lesion and area postrema lesion verification test 
 
DIO rats underwent area postrema lesion (APX) surgery 8 weeks after exposure to the HFD. 
To determine if the lesions were successful and complete, a verification test was performed, 
where the food intake response following amylin treatment (5 μg/kg, i.p.) was recorded. The 
preset criterion was that lesioned rats showing 15% or greater reduction of food intake 
following amylin treatment would not be included in the study.   
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Figure 5.12.: Mean ± SEM food intake 1 (A), 2 (B), and 4 h (C) after dark onset of sham- 
and area postrema-lesioned rats treated with saline (white bars) or amylin (5 μg/kg i.p., 
black bars) immediately before dark onset.  
 
 
At no time point following the injection did amylin reduce food intake in APX rats (Figs. 
5.12A-C). Though there was tendency for amylin to reduce food intake in sham-lesioned rats 
60 min after application (Fig. 5.12A), this effect unfortunately was not significant and a clear 
pre-mortem distinction between operation groups was therefore not possible.  
 
 
5.3.3 Results of Experiment 3b 
Effect of chronic peripheral infusion of amylin on body weight 
 
Sham- and AP-lesioned DIO rats were then surgically implanted with minipumps that infused 
saline or amylin (100 μg/kg/day; s.c.) for 14 days. Figure 5.13A shows that sham-lesioned 
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animals infused with amylin showed a significant reduction in body weight gain compared to 
shams receiving saline (p<0.05). Lesioning the AP blocked this effect, so that no difference in 
body weight gain was observed in APX rats infused with saline or amylin (Fig. 5.13B). Figure 
5.13C depicts the changes in body weight for all four groups over the entire duration of the 
study.  
 
 
 
Figure 5.13: BW gain of sham rats after minipump implantation (A), BW gain of APX 
rats after minipump implantation (B), data are from day 17 after implantation of 
minipump ;BW development over time of all groups after minipump implantation (C). 
Rats carrying saline minipumps are shown in white bars, and those with amylin 
minipumps are shown in the black bars. Symbols denote significant differences between 
saline and amylin treatment;  *p<0.05 
 
While amylin reduced the rate of body weight gain in sham-lesioned rats, APX rats showed 
no difference in body weight development regardless of the minipump infusate. Interestingly, 
APX rats generally gained more weight than sham-lesioned rats during the 2-week 
experimental period. 
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5.3.4 Results of Experiment 3c 
Effect of amylin infusion on leptin-induced anorexia 
 
Chronic infusion of amylin reportedly restored leptin sensitivity in obese leptin resistant rats 
(Roth et al., 2008). Here we tested if amylin had the same effect under our experimental 
conditions and whether amylin’s leptin-sensitizing effect was also seen in DIO rats after 
lesioning the AP. We first assessed leptin-induced anorexia following treatment with amylin 
for one week. Sham and APX rats equipped with minipumps infusing saline or amylin were 
fasted for the last 2 hours of the light phase, and shortly before dark onset received an 
injection of either distilled water or leptin (5 mg/kg, i.p.). Food intake was measured 4 h (Fig. 
5.14A) and 24 h (Fig. 5.14B) after injection. Surprisingly, and in contrast to our expectations 
based on the study by Roth and colleagues (Roth et al., 2008), leptin did not reduce food 
intake under any of the conditions tested.  
 
 
 
Figure 5.14.: Mean ± SEM food intake 4 (A), and 24 h (B), after dark onset of sham or 
APX rats pretreated with subcutaneous, chronically-infused vehicle or amylin (100 
μg/kg/day), followed by an injection of saline (white bars) or leptin (5 mg/kg i.p., black 
bars) immediately before dark onset.  
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5.3.5 Results of Experiment 3d 
Effect of amylin infusion on leptin-induced STAT3 phosphorylation 
 
It was also reported that amylin’s effect to restore leptin sensitivity coincides with an 
enhanced leptin-induced STAT3 phosphorylation in the VMH of DIO rats. Thus, in a follow-
up experiment, we tested if amylin treatment restores leptin-induced phosphorylation of 
STAT3 in DIO rats after lesioning the AP. As before, rats were fasted for 2 hours, treated 
with distilled water or leptin (5 mg/kg, i.p.) before dark onset, and perfused 45 min later 
according to the pSTAT3 protocol described above.  
 
 
Figure 5.15: Representative fluorescent photomicrographs showing pSTAT3 
immunoreactivity in the VMH 45 min after treatment with vehicle (A) or leptin (B) in 
sham rats infused with NaCl for 14 days; or after treatment with vehicle (C) or leptin (D) 
in sham rats infused with amylin(100 μg/kg/day) for 14 days. Scale bar = 200 µm 
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Hypothalamic brain slices were processed for pSTAT3 immunohistochemistry, 
photomicrographs of the sections were captured, and the pSTAT3-positive cells within the 
VMH were quantified. The leptin-induced pSTAT3 response in saline and amylin treated 
sham-lesioned rats is shown in Figure 5.15. Leptin induced a comparable number of pSTAT3 
in the VMH of rats infused with either saline (Fig. 5.15B) or amylin (Fig. 5.15D) for 14 days . 
 
 
 
 
Figure 5.16: Representative fluorescent photomicrographs showing pSTAT3 
immunoreactivity in the VMH 45 min after treatment with vehicle (A) or leptin (B) in 
APX rats infused with NaCl for 14 days; or after treatment with vehicle (C) or leptin (D) 
in APX rats infused with amylin (100 μg/kg/day) for 14 days. Scale bar = 200 µm 
 
Figure 5.16 shows photomicrographs of animals which underwent an area postrema lesion 
before testing. Compared to sham rats, leptin treatment resulted in a comparable number of 
pSTAT3-postive cells in the VMH of AP-lesioned rats infused with saline (Fig. 5.16B) or 
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amylin (Fig. 5.16D) for 14 days. The number of pSTAT3-postive cells in leptin-treated APX 
rats was also similar that in sham-lesioned rats, as can be seen in the quantification shown in 
Figure 5.17. Hence, an intact AP did not seem to be necessary for this effect of leptin. 
 
 
 
Figure  5.17: Quantification of pSTAT3 immunoreactivity in slices of VMH collected 
from sham and APX rats treated with saline vehicle or amylin (100 μg/kg/day) for 14 
days, followed by acute injection of vehicle (white bars) or leptin (5 mg/kg i.p.; black 
bars) 45 min before sacrifice.  
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6 Discussion 
6.1 Does Bay 73-6691 prolong amylin’s anorectic action? 
The aim of this study was to test the hypothesis that the PDE9 inhibitor, Bay 73-6691, may 
enhance and prolong amylin’s anorectic action by blocking the degradation of cGMP, the 
second messenger mediating the effect of amylin. It is critical to initially state that throughout 
our experiments we encountered the problem that the ability of amylin to reduce food intake 
was often blunted or absent. Since amylin’s anorectic effect was the basis for testing the effect 
of Bay 73-6691, it is difficult to evaluate the results of some trials. In the cases that we 
observed a reliable amylin effect, we could see four main findings:  
 
1) Bay 73-6691 did not prolong the anorectic effect of amylin under most conditions. 2) The 
results suggest that the acute administration of Bay 73-6691 alone had a small anorectic effect, 
possibly by enhancing the effects of endogenous amylin or other satiating peptides. 3) These 
results did not seem to occur due to malaise, since Bay 73-6691 did not elicit a conditioned 
taste aversion. 4) Finally, we observed that rats pretreated with Bay 73-6691 showed a 
significantly higher number of amylin-induced c-Fos-positive cells in the area postrema, 
compared to animals that received the vehicle/amylin treatment.  
 
6.1.1 Effect of central administration of Bay 73-6691 on the action of peripheral 
amylin 
In the trials where Bay 73-6691 was administered centrally and acutely, we did not observe an 
enhancing effect of PDE9 inhibition on amylin’s anorectic effect; however we saw a tendency 
for Bay 73-6691 on its own to reduce food intake. In experiment 1a, amylin significantly 
reduced food intake for the first 2 hours in rats pretreated with vehicle. The group which 
received Bay 73-669 pretreatment followed by vehicle consumed a similar amount of food as 
the vehicle/amylin treated group. It seemed that Bay 73-6691 was sufficient to slightly reduce 
eating, similar to the effect produced by amylin alone. This raised the question if Bay 73-6691 
might enhance the action of endogenous amylin, or other satiating hormones. However, when 
Bay 73-6691 was given in combination with exogenous amylin, we did not observe a 
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heightened anorectic effect, but rather an effect similar to the one seen in the Bay 73-
6691/vehicle group.  
 
To determine if the dose of Bay 73-6691 was just too low to enhance exogenous amylin, we 
increased the dose of Bay 73-6691 to a 20 μg bolus injection in experiment 1b. Under these 
conditions, we observed a significant reduction in food intake after 4 hours in the Bay 73-
6691/amylin group, as compared to the Bay 73-6691/vehicle group; at this time point, amylin 
alone had no longer an effect of eating. This suggests an interaction of amylin and the PDE9 
inhibitor, indicating therefore that Bay 73-6691 prolonged amylin’s action. As observed in 
experiment 1a, the Bay 73-6691/vehicle group again displayed a reduction in food intake, 
compared to the vehicle only group, during the first 2 hours similar to the vehicle/amylin 
group.  
 
According to the outcome of experiment 1b we postulated that the timeframe of Bay 73-
6691’s action might be different than the previously-suggested half life of appoximately 2 
hours (van der Staay et al., 2008). We therefore designed an additional experiment in which 
we took into account the potentially longer time to the onset of the drug’s action. However, 
even with a longer delay of 3 hours between Bay 73-6691 and amylin treatments, neither an 
effect of amylin nor of the PDE9 inhibitor was seen. Aside from the data by van der Staay and 
colleagues, little is known about the time course of Bay 73-6691 action on cGMP levels. A 
recent study showed that subcutaneous administration of another PDE9 inhibitor, PF-4449613, 
elevated cGMP concentration in cerebrospinal fluid for four hours after treatment, with the 
peak effect observed between 30 and 60 minutes (Kleiman et al., 2012) Unfortunately, similar 
experiments have not been carried out examining Bay 73-6691’s effect on central cGMP 
levels. Thus, it would be advantageous to develop techniques that would allow us to track 
changes in cGMP in the area postrema following BAY 73-6691 treatment, and then determine 
the period of highest activity of Bay 73-6691, as well as additional pharmacokinetic details. 
 
Due to the highly vascularized area postrema, we questioned whether acute infusions of Bay 
73-6691 into the 4th ventricle might be rapidly washed out prior to interacting with neurons of 
the AP. Thus, we designed an experiment where the animals received a chronic infusion of 
the PDE9 inhibitor into the 4th ventricle. Variants of the acute central trials described before 
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were repeated, but Bay 73-6691 was administered chronically into the 4th ventricle by using 
minipumps, and animals were housed in BioDAQ® cages to continuously monitor feeding 
behavior. Unfortunately and for unknown reasons, rats did not show a significant anorectic 
response to amylin under these test conditions. Further, chronic central treatment with Bay 
73-6691 had no additional effect on feeding behavior, regardless of acute treatment with 
saline or amylin. Because little is known about the chemical properties of Bay 73-6691 under 
our test conditions, we cannot rule out that Bay 73-6691 did not remain stable and active in 
DMSO for 14 days. The experiment was also difficult to evaluate because we did not have a 
secondary marker to confirm that Bay 73-6691 actually penetrated the brain and modulated 
cGMP levels in the predicted way.  
 
We took advantage of the continuous food intake monitoring by the BioDAQ® system to 
determine if there were any differences in baseline meal parameter between vehicle- and 
PDE9 inhibitor-treated rats. Analysis of these data revealed no difference in meal size, meal 
number, IMI, latency to feed, or total food intake between the rats receiving chronic central 
treatment of vehicle or Bay 73-6691. While we did not observe an effect of Bay 73-6691, the 
results of the meal pattern analysis was somewhat surprising. Rats of similar size and body 
weight had been reported to consume an average of 9.4 nocturnal meals averaging in size of 
2.3 g with an average intermeal interval of 65.5 min (Zorrilla et al., 2005). Compared to these 
baseline meal properties, both groups of animals in our study consumed fewer (4) but larger 
(6-7 g) meals, and the latency to the first meal in the dark phase was delayed by about 45 to 
90 min after dark onset. In fact, the meal patterns of both groups bear some resemblance to 
those observed in rats following a lesion of the AP (Stricker et al., 1997; Brägger, 
unpublished findings). This posed the question of whether these changes in feeding behavior 
originated from chronic central infusion of a DMSO-based vehicle. While the potential side 
effects of DMSO application are discussed in greater detail in the following section, these 
results suggest that DMSO may have caused some damage to the area postrema neurons 
leading to an alteration in meal patterns and subsequently to the sensitivity to amylin. On the 
other hand, the results of the terminal c-Fos study in these chronically-infused animals 
suggested that this may not have been the case, because a c-Fos response in at least some AP 
neurons was still detectable. Furthermore, the latter results showed that even if treatment with 
Bay 73-6691 did not have an impact on food intake, it did enhance amylin-induced c-Fos 
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signaling in the AP; rats receiving Bay 73-6691 and amylin had a significantly higher number 
of c-Fos-positive cells than rats treated with Bay 73-6691 and saline, which was an effect not 
observed in rats chronically infused with vehicle. Therefore, if DMSO had a negative effect 
on the neurons in the area postrema, it certainly did not cause damage to all of them; 
nonetheless, it cannot be excluded that such a high concentration of DMSO (75% of total 
volume) might partially damage neurons in the AP.  
 
6.1.2 Effect of peripheral administration of Bay 73-6691 on amylin action 
Corresponding to what we had observed after central administration of Bay 73-6691, neither 
an effect of amylin nor an effect of the PDE9 inhibitor was detectable in studies where Bay 
73-6691 was administered peripherally. Because we failed to produce a reliable anorectic 
effect of amylin in the first trial, we decided to repeat this experiment with a different strain of 
rats and by modifying the route of amylin administration; however, these attempts also failed 
to produce an effect of amylin on food intake. The lack of an amylin effect under vehicle 
control conditions made it difficult to analyze the data and to interpret a potential role of Bay 
73-6691 in modulating amylin action. Because we observed no effect of amylin on feeding 
behavior, we suspected that the rats were insensitive to amylin and designed an experiment to 
verify our suspicion. Hence, in a terminal experiment, animals were peripherally treated with 
different concentrations of amylin or with a control treatment of CCK, and the brains were 
then processed for c-Fos immunohistochemistry. The results clearly showed that even 50 
μg/kg amylin induced a weaker c-Fos expression in the AP than the the control injection of 3 
μg/kg CCK; lower doses of amylin induced very little or no c-Fos in the AP. These results 
suggest that these rats exhibited blunted sensitivity to amylin. The diminished sensitivity was 
evident throughout our set of experiments, because amylin often failed to induce a sufficient 
and reliable anorectic effect. Because we did not observe increased expression of c-Fos in the 
AP of amylin-treated rats, we first assumed that the quality or the level of sensitivity of the c-
Fos antibody was deficient. However, this theory was contradicted by the satisfactory CCK-
induced c-Fos response. The relatively short fasting in this experiment time could have been 
another critical issue. We used a fasting time of 2.5 h, and while it is possible that a longer 
fasting time would have led to a stronger c-Fos response (Michel et al., 2007; Zuger et al., 
2013), we observed in experiment 1f that 2.5 h was actually sufficient to induce a clear c-Fos 
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response. Further, in experiment 1d, we included control brain tissue from a rat which was 
also fasted for exactly 2.5 h, and received an injection 5 μg/kg amylin at dark onset, the only 
difference was that no vehicle or Bay 73-6691 was administered. This control rat displayed a 
clear c-Fos response, compared to brain slices from all other rats, suggesting that the fasting 
time was less of an issue, but that the infusion of vehicle or Bay 73-6691 could have 
somehow contributed to the blunted c-Fos response.  
 
It is unclear why in most experiments of this study amylin did not induce an anorectic effect. 
We hypothesized that there might be a connection to the dimethyl sulfoxide (DMSO) that was 
used as a vehicle for Bay 73-6691. DMSO is an amphipathic molecule, with a highly polar 
domain and two apolar groups, which makes it a very good solvent for different drugs; 
however, DMSO is not an inert substance. DMSO itself is used as a treatment for different 
diseases like the amelioration of interstitial cystitis (Parkin et al., 1997), rheumatologic 
diseases, dermatologic diseases and chronic prostatitis (Shirley et al., 1978). Treatment of 
traumatic brain edema (Ikeda and Long, 1990) relies on DMSO’s ability to cross the blood 
brain barrier (Broadwell et al., 1982), and it also has an antipsychotic effect (Smith, 1992). 
There are several other pathologic conditions in which DMSO serves as a treatment or as a 
solvent for delivering drugs. One study performed in guinea pigs papillary muscle suggest 
that DMSO, due to his hyperosmolarity, induces cell shrinkage; a 10% DMSO solution 
induce a cell shrinkage similar to 1.5 times hyperosmotic sucrose solution (Ogura et al., 1995). 
Various side effects of DMSO have also been reported, including chills, fever (Stroncek et al., 
1991), severe hemolysis (Samoszuk et al., 1983), and gastrointestinal effects like nausea and 
vomiting (Davis et al., 1990). 
 
While there are some reports that DMSO causes side effects like nausea and vomiting (Davis 
et al., 1990), rats treated with DMSO vehicle or Bay 73-6691 did not show signs of malaise in 
our conditioned taste aversion paradigm. However, in the CTA test, vehicle and Bay 73-6691 
were given peripherally, and the vehicle only contained 20% DMSO. Thus, we can not 
exclude the possibility that animals, which received 75% DMSO centrally, could have 
suffered from malaise. It is possible that a different CTA paradigm, inducing a CTA after 
centrally administered Bay 73-6691, might produce a different outcome; malaise following 
DMSO or Bay 73-6691 would then perhaps have been detected. It is safe to say that DMSO is 
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often used as a solvent, but its side effects are commonly neglected. With its variable uses and 
effects, it is possible that DMSO also interfered in our experiments in an unknown way.  
 
Even though our experiments with Bay 73-6691 beared some inherent risk because very little 
is known about the in-vivo effects of this drug, the lack of an amylin effect in many of our 
experiments was quite unforeseen. Interestingly, it has recently been reported by Woods and 
Langhans (Woods and Langhans, 2012) that effects observed following treatment with 
compounds that alter food intake can sometimes be difficult to reproduce from trial-to trial or 
from lab-to-lab. Woods recounts problems from his own laboratory relating to icv infusion of 
insulin; for many years, central insulin produced a stable anorectic effect, but at some point 
the effect was not reproducible. Regardless of whether the same original conditions were used 
or the conditions were optimized, the effect remained absent, until suddenly it appeared again. 
The reason why the anorectic effect of central insulin disappeared or reappeared remained 
unclear. Similar inconsistencies have been observed for the peptides that reduce food intake, 
including leptin and PYY, as well as for signals that are typically thought to increase food 
intake, such as mercaptoacetate and NPY (Woods and Langhans, 2012) What exactly happens 
mechanistically when a peptide or drug suddenly does not seem to reproduce well-described 
effects is often unclear. Similarly, in our experiments with peripheral administration of Bay 
73-6691, we were unable to induce a clear anorectic effect of amylin, somehow confirming 
this finding of Woods. One explanation for this phenomenon might be a learning effect in the 
animals. Woods suggested that animals might learn to ignore drugs as a satiation factor when 
they are consistently stimulated with it under a specific situation. Therefore we can’t exclude 
that the lack of amylin’s anorectic effect and the weak or absent c-Fos expression, may have 
had its origin in some learning effect, which desensitized our animals against amylin.  
 
 
6.2 The role of the AP in amylin-induced restoration of leptin sensitivity  
The aim of the second study was to determine the role of the AP in the amylin-induced 
restoration of leptin sensitivity in DIO rats. The experiment’s success heavily depended on 
our ability to replicate the findings of Roth and colleagues (Roth et al., 2008). Roth tested the 
impact of chronic amylin infusion (100 μg/kg/d; 14 days) alone and in combination with 
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leptin (500 μg/kg/d; 14 days) on body weight, food intake and the leptin-induced pSTAT3 
signal in the brain of DIO-prone rats. Amylin treatment decreased food intake and 
bodyweight compared to vehicle; in combination with leptin an additional 16% reduction in 
food intake and an additional 4% weight loss was achieved. In the same study, leptin alone 
had no effect, because DIO-prone rats are leptin-resistant. These results suggested clearly that 
amylin restored leptin sensitivity to produce synergistic effects on body weight. Roth also 
tested if amylin pretreatment restored leptin-induced pSTAT3 signaling in the hypothalamus 
and the hindbrain. Indeed, amylin pretreatment for 7 days led to a 43% increase in leptin-
induced pSTAT3 signaling in the VMH relative to vehicle-treated and pair-fed rats.   
 
Unfortuntely, we were unable to replicate these findings in our cohort of DIO rats, making the 
contribution of the AP in our paradigm using AP-lesioned animals difficult to decipher. In 
other words, we did not observe any impact of amylin pretreatment on leptin’s capacity to 
reduce food intake in an acute test in sham lesioned animals, nor any changes in leptin 
induced pSTAT3 signaling between the groups. All rats treated with terminal leptin mounted 
a pSTAT3 response, regardless of whether or not they were pretreated with amylin. While this 
indicated that rats were leptin sensitive, none of these rats showed a behavioral response to 
leptin. While we attempted to closely mimic the experimental design of Roth, some variations 
in our experiment possibly contributed to the disparate results. One difference in the 
experimental design was the DIO rat model. According to the methods established by Levin 
and colleagues (Levin et al., 1997) we genereated DIO rats by placing outbred Sprague 
Dawley rats on a high fat diet for two weeks, after which body weight and growth patterns 
were assessed. The tertile gaining the highest percentage of weight while on the high fat diet 
was designated DIO and used in our experiment. The rats were maintained on the high fat diet 
until the start of the chronic amylin treatment. The group of Roth used DIO-prone rats which 
are rats selectively bred over many generations for their propensity to become obese, even in 
the absence of a high fat diet. In fact, it is not clear from Roth’s study if the DIO-prone rats 
were ever given access to a high fat diet, which on its own may have effects on neuronal 
leptin sensitivity, even during short term exposure (Olofsson et al., 2013). While the two DIO 
rat models exhibit many similarities, the extent of amylin and leptin to synergize in our DIO 
outbred model had not been formally established before or compared to that in DIO-prone rat.  
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Our study also had slight modifications in amylin and leptin delivery times, doses, and 
vehicles. In both studies amylin was administered subcutaneously (100 μg/kg/day) for up to 
14 days; however in the Roth study, amylin was diluted in a vehicle of 50% DMSO, while we 
used saline as a vehicle. In both studies, chronic amylin treatment reduced body weight in 
intact DIO rats, however the effect of amylin appeared much stronger in Roth’s study, 
suggesting that use of a DMSO vehicle may actually have enhanced the effectiveness of 
amylin, or possibly preserved its activity. Differences in leptin treatment may also have 
altered our results. Roth tested the effect of chronic co-administration of leptin and amylin on 
food intake, while we opted to test whether chronic amylin infusion modified the feeding 
response to acute leptin treatment in DIO rats. Unlike the Roth study, we observed no effect 
of chronic amylin treatment on acute leptin, suggesting that either the synergy between 
amylin and leptin is only displayed when both treatments are given chronically, or that the 
dose of the acute leptin treatment was not high enough to elicit an anorexic response. Indeed, 
Roth’s group used a terminal dose of 15 mg/kg  leptin to induce pSTAT3 in the brain, 
compared to 5 mg/kg of leptin in our study. Interestingly, in our experiment all animals that 
were treated with leptin showed a pSTAT 3 response, regardless of whether they were treated 
with amylin or not. This indicates that the dose difference might not matter, at least not 
concerning the induction of a strong pSTAT3 response. 
 
The discrepancy between our results and those of Roth makes it difficult to conclude whether 
the AP is a critical brain center for the synergistic effects of amylin and leptin. We can 
confidently conclude that the area postrema is not required for leptin’s induction of the 
pSTAT3 signal in the VMH. Further, we have some additional data showing that leptin-
induced pSTAT3 in the NTS was also not altered in APX rats, again confirming the minor 
role of the AP in leptin signaling. The results of this experiment, unfortunately, do not shed 
new light on the mechanism underlying amylin and leptin’s interaction; the AP can neither be 
confirmed nor excluded as a critical site of action. Given the difficulties we encountered when 
trying to replicate Roth’s findings, it is clear that alternative strategies are necessary to test 
how amylin and leptin synergize to promote enhanced weight loss and reduction of food 
intake.  
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